HopeStage
Back to all studies
CompletedNCT04136873

CVL-231 for Schizophrenia: Safety and Drug Levels

About this titleRead the official source — NCT04136873

This study evaluated the safety of CVL-231 for people with schizophrenia.

Medication studyAges 18–55United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of CVL-231 for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations
Bentonville and 4 more locationsSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 15, 2019
Recruitment status
Completed
Enrollment listed in the registry
130
Sponsor
Cerevel Therapeutics, LLC
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 55 Years
Official registry ID
NCT04136873
Official title
Show the full official title

A Phase 1B Trial To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of CVL-231 in Subjects With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Bentonville · Little Rock · Lemon Grove

2 more locations
  • Long Beach
  • Marlton

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of CVL-231 for people with schizophrenia.

Who is behind this study?

The study sponsor is Cerevel Therapeutics, LLC.

Did this study involve medication?

Yes. The study involved medication, including CVL-231 and Matching Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies